Cristina Saura Manich

39PUBLICATIONS
410CO-AUTHORS
Molecular targetsPredictive and prognostic markersPsychosocial aspects of childbirth and perinatal mental healthHealth and ecological risk assessmentCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jul 13, 2026
Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors.

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Feb 03, 2026
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Rosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum

|Dec 01, 2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.

Mafalda Oliveira, Eva Ciruelos, Guillermo Villacampa

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

Pageof 7

Frequent Collaborators

15 joint publications

Mafalda Oliveira

9 joint publications

Joaquín Arribas

9 joint publications

Paolo Nuciforo

7 joint publications

Javier Cortès